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Alzheimer’s (AD) and Parkinson’s Diseases (PD) are common neurodegenerative disorders
growing in incidence and prevalence and for which there are no disease-modifying
treatments. While there are considerable complexities in the presentations of these
diseases, the histological pictures of these pathologies, as well as several rare genetic
predispositions for each, point to the involvement of maladaptive protein processing and
inﬂammation. Importantly, the common presentations of AD and PD are connected to
aging and to dysmetabolism, including common co-diagnosis of metabolic syndrome or
diabetes. Examination of anti-diabetic therapies in preclinical models and in some
observational clinical studies have suggested effectiveness of the ﬁrst generation insulin
sensitizer pioglitazone in both AD and PD. Recently, the mitochondrial pyruvate carrier
(MPC) was shown to be a previously unrecognized target of pioglitazone. New insulin
sensitizers are in development that can be dosed to full engagement of this previously
unappreciated mitochondrial target. Here we review molecular mechanisms that connect
modiﬁcation of pyruvate metabolism with known liabilities of AD and PD. The mechanisms
involve modiﬁcation of autophagy, inﬂammation, and cell differentiation in various cell types
including neurons, glia, macrophages, and endothelium. These observations have
implications for the understanding of the general pathology of neurodegeneration and
suggest general therapeutic approaches to disease modiﬁcation.
Keywords: Parkinsion’s disease, Alzhaimer’s disease (AD), mitochondria, autophagy, inﬂammation

OVERVIEW
Drug discovery efforts generally focus on narrowly deﬁned syndromes in search of precision
solutions. However, effective therapeutics for neurodegenerative diseases remain a signiﬁcantly
unmet medical need likely because of the broad and complex presentations and the limited
heritability of these progressive diseases. Alzheimer’s disease (AD) is the most common cause of
age-related dementia and manifests in a variety of presentations and symptoms (Scheltens et al.,
2021). Work in twins suggests that AD, as currently diagnosed, may be 60–80% heritable and over
40 risk-associated genetic variations have been identiﬁed. Some these mutations seem to ﬁt with the
histological presentation of disease, and indeed these insights have facilitated the generation of
animal models that can recapitulate aspects of AD pathology. Parkinson’s disease (PD), the most
common form of neurodegeneration associated with movement disorders, is also partially heritable
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with some mutations that can also produce symptoms in animal
models (Simon et al., 2020). In this case, motor symptoms can
also be produced by speciﬁc toxins, which provides relevant
information as to pathophysiology, particularly with respect to
the loss of function in the dopamine system.
Unfortunately, while advances in understanding the genetics
of some rare subsets of AD and PD have identiﬁed rational
therapeutic targets and some animal models have been created,
effective disease modifying agents in clinical trials have not been
forthcoming. Efforts are complicated by the fact that individual
mutations in the spectrum of AD and PD, even when they reﬂect
a component of the pathological phenotype, describe at best a
very small percentage of people with these diseases. Disease
modifying therapeutics have remained elusive and these
neurodegenerative diseases remain a signiﬁcant afﬂiction of
aging and a major unmet need in global health care.
Herein, we discuss an alternate approach to treating
neurodegenerative diseases by correcting the upstream
metabolic
drivers
that
are
in
common
across
neurodegenerative diseases. We summarize data generated
from the growing descriptions of the pathophysiology of AD
and PD and the emerging understanding of the molecular action
of compounds known as insulin sensitizers. The conﬂuence of
these data suggests an approach to slowing disease progression by
reprogramming metabolism. Metabolism impacts myriad cellular
and
molecular
processes
that
modulate
known
pathophysiological
mechanisms
including
autophagy,
inﬂammation, and cell differentiation in multiple cell types.
Thus, a metabolic approach would not only impact multiple
molecular pathways in parallel but would also have the potential
to positively impact both AD and PD.

TABLE 1 | Common factors in AD and PD.

Age
Mitochondrial function
Protein aggregates
Inﬂammation
Genetic/autophagy
Toxin-induced
Metabolic/T2D

PD

yes
yes
amyloid
yes
yes
no
yes

yes
yes
α-synuclein
yes
yes
yes
yes

might reverse these histological manifestations (Jouanne et al.,
2017; Lozupone et al., 2020; Tolar et al., 2020; Yu et al., 2021).
While these plaques are the key signature of AD, there are many
abnormalities in brain structure, function, and metabolism that
have been discovered over the years.
PD is neurodegenerative disease with characteristic motor
dysfunction. However, the clinical presentation often includes
many non-motor defects ranging from constipation to
neuropsychiatric issues (Simon et al., 2020; Vijiaratnam et al.,
2021). The physical presentation includes loss of function of the
dopamine producing neurons in the midbrain and can include
cytosolic aggregations of misfolded protein that may include αsynuclein. Environmental toxins can trigger the loss of these
motor neurons, but there are also rare mutations, including those
coding for α-synuclein and proteins related to mitochondrial
homeostasis, that predispose to the development of PD. In
general, all the known risk-associated factors impinge on
mitochondrial function, oxidative stress, impaired autophagy
and neuroinﬂammation (Vijiaratnam et al., 2021). Like AD,
the incidence of PD increases with age (Trist et al., 2019;
Vijiaratnam et al., 2021). Thus, although the affected
anatomical regions and the symptoms of these divergent
neurodegenerative diseases are very different, there are similar
factors involved in their pathological progression. As outlined
below, these considerations point to a critical role for
mitochondrial metabolism and frame an approach to
interventions.
A summary of common factors that inﬂuence disease
progression in both AD and PD is presented in Table 1. Of
these commonalities, the relationship between metabolism and
these neurodegenerative diseases is particularly interesting. There
is a conﬂuence among the associations of aging, metabolic
syndrome and type 2 diabetes in incidence and progression of
both AD and PD. Furthermore, a class of agents developed to
treat the insulin resistance of type 2 diabetes has demonstrated
positive clinical effects and, to the point of the current discussion,
addressable molecular connections of the pathophysiology to
metabolism.

Disease Incidence, Presentation, and
Implications From Genetic Studies
Alzheimer’s disease (AD) is a common disease associated with
aging that involves progressive loss of neurons and deposition of
plaques composed of the Aβ protein. The prevalence of AD is
continuing to increase, and it is currently the 5th leading cause of
death in the US for people over the age of 65. Critically, AD has an
oversized impact on public health because of the level of care
required as the disease progresses because patients may require
intensive and round the clock care for many years. While there
are clear differences in a clinical diagnosis of the various forms of
AD that differ from aging per se, age has a signiﬁcant impact on
disease progression regardless of the speciﬁcs of clinical diagnosis
(Toepper, 2017; Guerrero et al., 2021; Scheltens et al., 2021). The
physical presentation of AD is generally recognized as the
increased
presence
of
amyloid
plaques
and
hyperphosphorylated tau which can be detected on autopsy
and, more recently, by imaging techniques (Dani et al., 2016).
Rare mutations in the amyloid pathway may predispose to early
development of AD and insights from genetic data have led to the
development of animal models with defects in amyloid
metabolism that can mimic some of the AD pathology (Zhang
et al., 2020). As a consequence of these insights, many of the drug
discovery efforts directed at AD have targeted mechanisms that
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Impact of Dysmetabolism
Although the details of molecular mechanisms remain the subject
of much debate and investigation, metabolic dysfunction or
dysmetabolism is likely both a cause and consequence of
insulin resistance and type 2 diabetes mellitus (e.g., see
(Czech, 2017; Roden and Shulman, 2019)). As discussed
below, the spectrum of metabolic disturbance that includes
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type 2 diabetes is also strongly associated with AD and PD. While
“normal” aging and metabolic dysfunction do not share all of the
common neurodegenerative features of AD and PD, there are
common underlying mechanisms that may contribute to disease
progression (Tumminia et al., 2018; Frazier et al., 2019).
Abnormalities in brain insulin sensitivity are an early sign of
AD. Indeed, many have described AD as “Type III diabetes” (de la
Monte, 2014) due to many similarities in the metabolic
abnormalities that are observed. There are a number of facets
to metabolic dysfunction that impinge on progression of AD
including the observation that glucose metabolism is impaired in
affected brain regions in advance of cognitive decline. There is
also a growing understanding of the importance of insulin and
IGF-1 signaling in neural tissues (de la Monte, 2014; Arnold et al.,
2018; Xue et al., 2019; Potenza et al., 2021). Indeed, blocking
insulin signaling in a neuron-speciﬁc manner is sufﬁcient to
induce signs of Alzheimer’s in mice (Soto et al., 2019). An
extensive literature is building in this respect, but here we will
focus on the aspect of insulin resistance and mitochondrial
metabolism that connects to the ﬁrst therapeutic agents that
were developed to address insulin resistance.
The association between type 2 diabetes and PD has also
recently been reviewed (Aviles-Olmos et al., 2013; Cheong et al.,
2020). Observational studies show an increase in incidence and
severity of Parkinson’s symptoms in patients who have been codiagnosed with diabetes. Moreover, patients with PD have been
found to exhibit insulin resistance and impaired glucose
tolerance, two manifestations of dysmetabolism coincident
with diabetes. This has led to some small clinical trials using
incretin agonist antidiabetic agents that have shown positive
results (Athauda et al., 2017) suggesting the treatment of the
underlying hyperglycemia could be useful. Observational clinical
studies have shown a reduction in the incidence of PD in patients
with diabetes who were treated the insulin sensitizing agents
(Brauer et al., 2015; Hussain et al., 2020). Further scrutiny of these
results is of particular interest because of the growing knowledge
of the mitochondrial mechanism of action of these agents as
discussed below.
Mitochondrial function is a key common feature of
metabolism that connects AD, PD, and aspects of the
metabolic syndrome including diabetes (Pinti et al., 2019;
Wang et al., 2020a; Monzio Compagnoni et al., 2020;
Weidling and Swerdlow, 2020; Borsche et al., 2021; Potenza
et al., 2021). Mutations in the PINK1 and PRKN genes, which
encode proteins that play important roles in regulating
mitochondrial quality control, dynamics, and turnover, were
among the ﬁrst genes linked to development of PD
(Malpartida et al., 2021). Because of this linkage to mitophagy,
the autophagic processes that dispose of dysfunctional
mitochondria, there has been a great deal of interest in PD
therapeutics that stimulate autophagy or modulate
mitochondrial function. Similarly, in AD, a number of defects
in mitochondrial energetics, increased oxidative stress, ﬁssion/
fusion, and turnover have been noted (Wang et al., 2020b). A
number of potential triggers for mitochondrial abnormalities
have been identiﬁed, but existing data suggest that
mitochondrial dysfunction plays a causative role in the
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development and progression of AD. Therefore, targeting
mitochondrial metabolism to treat AD has also garnered a
great deal of attention.
Mitochondrial dysfunction initiates intracellular signaling
cascades that can impair many processes known to be
important in the progression of the disease including
autophagy, inﬂammation, and cellular responses to growth
factors. Obviously, mitochondrial dysfunction has implications
for many cell types in all tissues (Pinti et al., 2019). It is important
to note that this connection could be either because of a common
underlying pathology, for example as occurs with aging, or
because the metabolic dysfunction worsens other underlying
etiologies. For example, buildup of misfolded proteins enabled
by either a genetic predisposition and/or environmentallyinduced loss of function can themselves precipitate
exacerbation of the pathology creating a vicious cycle (Colca
and Feinstein, 2012; Torres et al., 2021). Therefore, therapeutics
that correct abnormalities in mitochondrial metabolism and elicit
beneﬁcial effects on processes like autophagy and
neuroinﬂammation may be ideal candidates for treating
neurodegenerative disease.
A review of the clinical studies of anti-diabetic drugs on the
incidence of dementia in people with diabetes demonstrated a
unique efﬁcacy of pioglitazone (McMillan et al., 2018). Of
particular relevance to this review, which seeks to connect the
molecular mechanisms involved, a number of clinical
observations and preclinical studies in neurodegenerative
disease have also shown some intriguing results with
pioglitazone. A brief background of pioglitazone is presented
below in order to frame the discussion that follows.

Insulin Sensitizers and Preclinical and
Clinical Studies With Pioglitazone
In the 1990s, three drugs that improved insulin sensitivity
(troglitazone, rosiglitazone, and pioglitazone) were approved
for the treatment of type 2 diabetes. These drugs all share a
common chemical structure; a thiazolidinedione (TZD) ring. As
we have previously reviewed, thiazolidinediones were selected
and developed in the mid 1980s based on their insulin sensitizing
effects before there was a molecular hypothesis of their
mechanism of action (Colca, 2006; Colca and Kletzien, 2006).
Years after these compounds were selected and entered into
clinical development, they were found to be direct activators
of the transcription factor PPARγ and subsequently, many drug
discovery programs were focused on ﬁnding additional and more
potent PPARγ activators (reviewed in (Soccio et al., 2014)).
However, it is now recognized that PPARγ activation is
associated with the side effects that have plagued this class of
drugs. Troglitazone, the ﬁrst compound from this class to gain
registration for treatment of type 2 diabetes, was removed the
market due to compound-speciﬁc idiopathic hepatoxicity.
Rosiglitazone was initially removed and then limited in use
because of potential increases in cardiovascular disease and
heart failure. Pioglitazone remains the only marketed
therapeutic from this class that is still utilized clinically to any
signiﬁcant extent (Nissen and Wolski, 2007; Rizos et al., 2016;
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DeFronzo et al., 2019; Le et al., 2020). Even so, and although the
pharmacology of pioglitazone has broader implications including
prevention of cardiovascular and metabolic liver disease
(DeFronzo et al., 2019; Le et al., 2020), it is used only as a
second or third line anti-diabetic agent based on tolerability issues
related to its direct activation of PPARγ, which results in ﬂuid
retention and the potential for bone loss. Interestingly,
pioglitazone is 10-fold less potent PPARγ agonist compared to
rosiglitazone and is as effective as an insulin sensitizer, but with a
greater safety margin. This experience had suggested that other
molecular targets may mediate some of its beneﬁcial
pharmacology (Colca and Kletzien, 2006).
Pertinent to this discussion, there have been numerous
preclinical studies with TZDs showing multiple beneﬁcial
effects in models of neurodegeneration. In alignment with the
earlier discussion on the importance of mitochondria in these
pathologies, many of these studies have suggested that the actions
of these agents on the mitochondria might be a key factor in the
pharmacology (reviewed in 34). A more recent intriguing
observational clinical study conducted in Germany
demonstrated a 47% reduction in the incidence of dementia in
people with diabetes who had been treated long-term with
pioglitazone. In fact, for subjects treated more than 2 years,
their risk of developing dementia was even lower than subjects
who had not developed diabetes (Heneka et al., 2015). An
excellent summary of all the preclinical and clinical results
with TZDs has recently been published (Saunders et al., 2021).
Although there have been many positive studies conducted and
published with pioglitazone, a prospective study with very low
dose pioglitazone was stopped for futility (Burns et al., 2021). The
very low dose (0.8 mg) was used to avoid side effects that can be
seen with the more commonly given clinical doses (30 and
45 mg). It is likely that this study failed because of the low
exposures achieved, since another review of multiple clinical
studies with pioglitazone points out that positive effects of
pioglitazone on dementia are both dose- and time-dependent
(Chou et al., 2017). The increased exposure required for clinical
efﬁcacy may be due to the requirement to engage other molecular
targets such as the mitochondrial target for the TZDs.

developed for treatment of type 2 diabetes acted as inhibitors
of MPC activity by directly binding to the MPC complex
(Divakaruni et al., 2013; McCommis et al., 2015; McCommis
and Finck, 2015). The effects of pioglitazone on pyruvate
metabolism may also be mediated via induction of pyruvate
dehydrogenase kinase, which inhibits pyruvate oxidation by
pyruvate dehydrogenase, and remodeling of mitochondrial
lipids to alter mitochondrial function (Shannon et al., 2021).
Thus, not only the entry of pyruvate but the modiﬁcation of its
downstream metabolism may be impacted by TZD use.
Two inner mitochondrial membrane proteins, MPC1 and
MPC2, constitute the MPC, which is the obligate entry point
of pyruvate into the mitochondrion (Bricker et al., 2012; Herzig
et al., 2012; Sharma et al., 20192019). Since the primary routes of
pyruvate synthesis are glycolysis or by lactate dehydrogenase,
which are cytosolic processes, and the enzymes that metabolize
pyruvate (pyruvate dehydrogenase and pyruvate carboxylase) are
exclusively localized in the mitochondrial matrix, the MPC
catalyzes an important regulatory step in intermediary
metabolism. While it may seem counterintuitive that
suppressing pyruvate metabolism is beneﬁcial for treating
metabolic disease, genetic deletion of the MPC in many tissues
is well tolerated and protects mice from obesity and/or diabetes.
For example, liver speciﬁc MPC deletion attenuated the ﬂux of
pyruvate into the gluconeogenic pathway to suppress liver
glucose production in obese mice (McCommis et al., 2015).
Deletion of the MPC in skeletal muscle protected mice from
obesity and improved their metabolic proﬁle in association with
enhanced fatty acid oxidation (Sharma et al., 2019). Indeed,
slowing the mitochondrial entry of pyruvate through the MPC
results in enhanced use of other substrates including fatty acids
and amino acids (McCommis et al., 2015; Divakaruni et al., 2017;
Buchanan and Taylor, 2020), which may mediate some of the
beneﬁcial effects of MPC inhibition. Indeed, in addition to
neurodegenerative diseases, identiﬁcation of novel inhibitors of
the MPC has garnered attention as a potential treatment of a
variety of diseases including type 2 diabetes, NASH, cancer, and
even hair loss (McCommis et al., 2017; Liu et al., 2021).
It is likely that MPC inhibition modulates the activity of
various energy-sensing signaling cascades such as AMPactivated protein kinase (AMPK), NAD + -sensing
deacetylases, or the mechanistic target of rapamycin (mTOR)
kinase. Since these signaling pathways are known to regulate
insulin sensitivity, inﬂammation, and autophagy, which are
cellular processes known to be involved in the response to
neurodegenerative stimuli, inhibition of the MPC may mediate
beneﬁcial effects by modulating the activity of these energysensing signaling cascades.
Alternatively, or in addition, other work has demonstrated a
beneﬁcial effect of MPC inhibition on neuronal death in
response to excitatory amino acids. Divakaruni and
colleagues showed that MPC inhibitors protected neurons at
least in part by stimulating the metabolism of glutamate and
other amino acids as an adaptive response to diminished ﬂux
through the MPC (Divakaruni et al., 2017). Since excitotoxic
neuronal death has been implicated in the pathogenesis of
neurodegenerative disease, the effects of MPC inhibition on

The Discovery of the Mitochondrial Target
of TZDs and Implications to Mitochondrial
Mechanisms
Although the general dogma is that pioglitazone acts via direct
transcriptional regulation of the PPARγ nuclear receptor, as
discussed earlier, pioglitazone was selected for development
based on functional screens without regard or knowledge of
mechanism. Subsequently, binding assays using subcellular
fractions from both liver and brain demonstrated that tritiated
pioglitazone binds primarily to mitochondrial membranes (Colca
et al., 2004). Subsequent work using a pioglitazone-based,
125
I-labeled photoafﬁnity crosslinker and unbiased proteomics
revealed that the mitochondrial target of the TZDs was the
mitochondrial pyruvate carrier (MPC) (Colca et al., 2013a;
Colca et al., 2014). Studies conducted in multiple cell types
conﬁrmed that insulin-sensitizing TZDs that had been
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FIGURE 1 | Metabolic connections to molecular mechanisms common in AD and PD.

pioglitazone metabolite in both preclinical models and in
man (Colca et al., 2013b). MSDC-0160 and its primary
hydroxy metabolite have limited ability to bind to and
directly activate PPARγ while maintaining the antidiabetic
pharmacology of pioglitazone (Chen et al., 2012; Colca et al.,
2013b; Tanis et al., 2018). The active metabolite of MSDC0160 has also been shown to readily cross the blood-brainbarrier in rodent models (Peelaerts et al., 2020). The potential
utility of this approach is supported by clinical efﬁcacy and
safety as discussed below.
MSDC-0160 has been studied in a Phase 2 dose-ranging study
in subjects with diabetes where it demonstrated the same antidiabetic activities as pioglitazone without evidence of dosetolerability issues (Colca et al., 2013c). A 3-months Phase 2a
clinical study of people with mild to moderate AD without
diabetes evaluated the potential of MSDC-0160 treatment to
maintain 18F-2-FDG PET uptake in the lateral temporal
cortex, medial temporal cortex and anterior cingulate-medial
frontal cortex, areas known to decline in parallel with
measures of cognition. When these regions were compared to
the cerebellum, the decline in the placebo group (N = 13) was
prevented in the MSDC-0160-treated patients (N = 16). These
results are supportive of a neuroprotective effect. There were also
several other brain regions, typical of amyloid deposits, that
demonstrated a treatment-induced decrease in the 18F-2-FDG
PET uptake. This would be expected of an anti-inﬂammatory
action, which the authors suggest should be directly evaluated in
future clinical trials. The study was not powered to detect changes
in cognition, however ADAS-Cog measurements tended to
worsen in the placebo group while there was no change in the
MSDC-0160-treated group (Shah et al., 2014).

the accumulation of excitotoxic amino acids could play a role
in the therapeutic pharmacology.
Our understanding of the speciﬁc role of that the MPC plays in
regulating metabolism in various cell types is now growing based
on a variety of cell type-speciﬁc knockouts (Gray et al., 2015;
McCommis et al., 2016; McCommis et al., 2017). The ability of
insulin-sensitizing TZDs to impact mitochondrial pyruvate
metabolism likely explains the pleotropic pharmacology that
has been observed over the years since their original discovery
(Colca, 2015). This pharmacology may include maintaining the
functionality of adipocytes, thus uncoupling of body weight from
insulin resistance (Colca and Scherer, 2022). The broad potential
of MPC activity modulation with respect to neurodegeneration
has recently been reviewed (Tang, 2019; Zangari et al., 2020) and
will be discussed in greater detail below.
As it became evident that direct activation of PPARγ could be
avoided while maintaining the interaction with the mitochondrial
target, a medicinal chemistry program was directed against the
direct activation of PPARγ (Chen et al., 2012; Tanis et al., 2018).
This has led to development of new TZDs for multiple indications
(Colca et al., 2013b). More recently screening efforts are
demonstrating the possibility of ﬁnding new molecular
scaffolds that can interact with and attenuate the ﬂux of
pyruvate through the MPC (Hegazy et al., 2022). It is not yet
clear whether all of these new scaffolds will interact with the
molecular target in a way that produces the same pleotropic
pharmacology as the TZDs like pioglitazone (Colca, 2015).

Studies With New TZDs
MSDC-0160 is an isomer of one the pioglitazone metabolites,
which is reduced to a stereoisomer of another minor
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FIGURE 2 | Involvement of multiple cell types in pathology and in repair mechanisms.

There has been more detailed study of the mechanistic
action of MSDC-0160 in pre-clinical models of PD. Ghosh
et al. (2016) demonstrated that MSDC-0160 could directly
protect against 1-methyl-4-phenylpyridinium (MPP+) insult
in murine and cultured human midbrain dopamine neurons.
This effect was caried over to mice that were treated with
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)– where
MSDC-0160 treatment improved locomotor behavior,
increased survival of nigral dopaminergic neurons, boosted
striatal dopamine levels, and reduced neuroinﬂammation.
Similar results were obtained in the slowly progressive
Engrailed1 (En1+/−) genetic mouse model of PD that
demonstrates a progressive loss of the differentiated status of
dopamine neurons. Progression of neurodegeneration in all of
these cellular and mouse models of PD was accompanied by
both an increase in mTOR activation and increased
inﬂammation. In each case, the beneﬁcial effects of MSDC0160 treatment coincided with a reduction in mTOR activity
and a decrease in inﬂammation toward the levels that occurred
in the control models. MSDC-0160 treatment also prevented
dopamine neuron loss in both an MPP+ and α-synuclein–based
Caenorhabditis elegans model. Selective knockdown of either
the C. elegans orthologs of MPC1 or mTOR prevented the
protective effects in these worms. MSDC-0160 treatment was
not effective in rodent models of alpha-synuclein
overexpression that did not exhibit underlying inﬂammation
or defective autophagy (Peelaerts et al., 2020).

Frontiers in Molecular Biosciences | www.frontiersin.org

Quansah et al. (2018) summarized the direct effects of
MSDC-0160 to attenuate pathologically-activated mTOR
and inﬂammatory pathways associated with regulating
autophagy in both neuronal and glial cells. In glial cells,
treatment with MSDC-0160 also attenuated the
inﬂammatory response to the bacterial toxin LPS.
Interestingly, the treatment with MSDC-0160 protected
mitochondria from the loss of oxygen consumption that
otherwise occurred both in neuronal cells exposed to MPP
+ toxin or a glial cell line exposed to LPS. Thus, the evidence
suggests that preservation of mitochondrial function in the
face of these challenges may be related to the downstream
neuroprotective and anti-inﬂammatory action.
In further support of the importance of pyruvate
metabolism in affecting PD pathology, Mallet et al. (2022)
have recently demonstrated that treatment with MSDC-0160
treatment improved motor behavior, decreased dopaminergic
denervation,
and
reduced
mTOR
activity
and
neuroinﬂammation in the unilateral 6-OHDA rat model of
PD. Metabolomic analysis indicated that reprogramming
pyruvate metabolism increased ketogenesis, beta oxidation
and glutamate oxidation and that multiple downstream
pathways were likely involved in the beneﬁcial effects. Thus,
while many molecular and metabolic mechanistic details
remain to be deﬁned, modiﬁcation of pyruvate metabolism
at the level of the MPC with compounds such as TZDs can be
neuroprotective.
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cerebral blood ﬂow and involves cell types not routinely
considered in drug development programs aimed at speciﬁc
neurodegenerative diseases (Figure 2). Ongoing work is
deﬁning the speciﬁc aspects involved in individual cell types
using cell-selective knock out of the MPC. This work will help
deﬁne which processes in which cells have the most important
impact of speciﬁc aspects of AD or PD. It is also important to note
that whereas the brain is usually considered privileged with
respect to immune regulation because of the blood brain
barrier, there are changes to blood brain barrier with aging
and dysmetabolism which can also contribute to
inﬂammation, neurodegenerative processes, and dementia
(Nortley et al., 2019; Guo et al., 2022; Kurz et al., 2022). A
more comprehensive understanding of interactions between cells
and their regulation by the metabolic milieu/changes in
mitochondrial function might also beneﬁt from the study of
more complex systems in vitro (Cenini et al., 2021).
In conclusion, there are multiple molecular mechanisms
associated with metabolism that impact the progression of AD
and PD. This is likely true of age-related neurodegenerative issues
in general, some of which may fall outside narrow clinical
deﬁnitions. The identiﬁcation of the MPC as a target of the
insulin sensitizer TZDs provides a logical explanation for the
pleotropic effects of these compounds. The elucidation of these
common pathways that mediate disease progression may
facilitate new approaches to disease-modifying treatments for
AD and PD.

METABOLIC CONNECTION TO
MOLECULAR MECHANISMS IN COMMON
TO AD AND PD
The collection of data summarized here point to the
importance of metabolism in the progression of both AD
and PD. While the milieu including glycemic state is likely
important (Cardoso and Moreira, 2020; Cheong et al., 2020),
we have summarized how underlying features relating to cell
metabolism, particularly as related to mitochondrial function
in speciﬁc cells, connect molecular mechanisms contributing
to the pathology. For example, the direct effects of
mitochondrial-directed TZDs on neurons and glia mitigate
against reduced autophagy and increased inﬂammation.
Growing evidence is connecting the MPC, now known to be
a direct molecular target of the ﬁrst generation TZD insulin
sensitizers, to function in multiple cell types. Figure 1
summarizes some of the currently recognized sites of
interaction that map onto cell processes involved in disease
progression. The immediately recognizable points of inﬂuence
are autophagy and inﬂammation, which have been shown to be
important in both glia and neurons, but which are obviously
important to regulation in many cell types. The multiple
molecular processes involved in this regulation include
nutrient sensing processes such as mTOR and downstream
regulatory transcriptional networks regulated both by
metabolites, redox, and oxygen levels which can modify
post-translational and epigenetic processes (Bertogliat et al.,
2020). The physical regions where the neurodegeneration
occurs deﬁne the speciﬁc syndrome. For example, failure to
clear misfolded proteins related to dopamine-producing
neurons will produce PD-like disease, while reduced
function in memory and executive function centers will
deﬁne a different set of symptoms.
Outcomes of disease progression and mitigation involve
effects on multiple cell types and also might involve
intercellular communication between various cell types of the
brain. This has important implications for a range of processes
from maintenance of synaptic connections to regulation of
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